Safety and effectiveness of collagenase clostridium histolyticum in the treatment of Peyronie's disease using a new modified shortened protocol

  title={Safety and effectiveness of collagenase clostridium histolyticum in the treatment of Peyronie's disease using a new modified shortened protocol},
  author={Amr Abdel Raheem and Marco Capece and Odunayo Kalejaiye and Tarek M. Abdel-Raheem and Marco Falcone and Mark James Johnson and Oliver Ralph and Giulio Garaffa and Andrew Nim Christopher and David J Ralph},
  journal={BJU International},
To evaluate the efficacy and safety of collagenase clostridium histolyticum (CCH; Xiapex®, Xiaflex®) in the treatment of Peyronie's disease (PD) using a new modified treatment protocol that aims at reducing the number of injections needed and reducing patient visits, thus reducing the duration and cost of treatment. 
Optimizing collagenase Clostridium histolyticum therapy for Peyronie’s disease using a novel approach with percutaneous needle tunnelling
To compare the efficacy and safety of a combined treatment of percutaneous needle tunnelling (PNT) and a modified collagenase Clostridium histolyticum (CCH) protocol (PNT/CCH) vs the modified
Intralesional collagenase Clostridium histolyticum in the management of Peyronie’s disease: current best practice
The purpose of this review is to examine pivotal trials demonstrating the efficacy of CCH, revisit viable candidates for treatment with intralesional injection therapy, and provide a summary of injection technique and appropriate management of patients receiving this treatment at the time of therapy and in follow up.
Collagenase Clostridium Histolyticum in the Treatment of Peyronie's Disease: Review of a Minimally Invasive Treatment Option
CCH continues to be the gold standard for non-surgical management of stable phase PD, in the absence of strong evidence supporting oral therapy agents and ongoing evaluation of extracorporeal shockwave therapy.
At what cost is collagenase clostridium histolyticum viable for treating Peyronie's disease in a public healthcare system?
Collagenase clostridium histolyticum is a recognized non‐surgical management for Peyronie's disease, licenced for use in the UK for patients with a palpable plaque and a curvature deformity of at
Evaluating collagenase Clostridium histolyticum administration protocols in the treatment of Peyronie's disease.
Treatment of Peyronie's disease with collagenase Clostridium histolyticum has gained world-wide adoption following the phase III clinical trials IMPRESS I and II, but the optimal treatment parameters remain largely unknown.
Collagenase clostridium histolyticum: a novel medical treatment for Peyronie's disease.
CCH is the gold standard non-surgical option in the management of PD and a new modified shortened protocol is suggested that will reduce the cost and duration of treatment without compromising the safety or efficacy of treatment.
Limited success with clostridium collagenase histolyticum following FDA approval for the treatment of Peyronie’s disease
The experience showed a less-robust response to CCH than previous studies and underscores the need for effective and clear patient counseling prior to the initiation of therapy with CCH for PD in the post-FDA-approval setting.
Collagenase clostridium histolyticum for the treatment of Peyronie's disease: a prospective Italian multicentric study
This prospective multicentric study confirms that the three‐injection protocol is effective enough to achieve a good result and to minimize the cost of the treatment of Peyronie's disease.


Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie's disease by subgroup: results from two large, double‐blind, randomized, placebo‐controlled, phase III studies
To examine the efficacy of intralesional collagenase Clostridium histolyticum (CCH) in defined subgroups of patients with Peyronie's disease (PD).
Role of collagenase clostridium histolyticum in Peyronie’s disease
Collagenase clostridium histolyticum has been clinically proven to be a safe and effective therapeutic option, demonstrating decreases in penile curvature and plaque consistency, as well as increases in patient satisfaction.
Therapeutic advances in the treatment of Peyronie's disease
Traction therapy, as part of a multimodal approach, is an underused additional tool for the prevention of PD‐associated loss of penile length, but its efficacy is dependent on patient compliance.
The medical management of Peyronie's disease
In this Review, the current medical treatment options available for the management of Peyronie's disease are discussed and a management algorithm is proposed.
The prevalence of Peyronie's disease: results of a large survey
Objectives To determine the prevalence of Peyronie's disease, a localized connective tissue disorder of the penile tunica albuginea, the symptoms of which include palpable plaque, painful erections
Clinical presentations of Peyronie's disease
A good clinical history and examination are all that are necessary to manage most patients with Peyronie's disease, and further investigation is only required in those men with erectile dysfunction or where surgery is indicated.
Is there a place for conservative treatment in Peyronie's disease?
There is a need for guidelines for nonsurgical therapies for patients with PD, but there is a paucity of evidence as to their efficacy.
The management of Peyronie's disease: evidence-based 2010 guidelines.
The real etiology of Peyronie's disease and the mechanisms of formation of the plaque still remain obscure, and conservative management is obtaining a progressively larger consensus among the experts.
Peyronie's disease (CME).
PyD does not invariably progress to a complete loss of the ability for sexual intercourse; indeed, using one or more of the treatment approaches outlined can, in most cases, result in adequate restoration of sexual function.